Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

NF Clinical Drug Pipeline

By June 5, 2014February 28th, 2024Science & Research

The Children’s Tumor Foundation has created chart shows all the drug treatments being tested for different conditions in NF1 and NF2 at the present time. This clinical drug pipeline includes completely new drugs, as well as variations of existing drugs, and new uses of existing drugs. Many of these potential treatments came out of research sponsored by the Children’s Tumor Foundation.

The chart below shows all the drug treatments being tested for different conditions in NF1 and NF2 at the present time. “Phase 0” is very early stage testing, “Phase 1” tests for drug safety, and “Phase 2” tests whether the treatment works. (Sometimes “Phase 1” and “Phase 2” are combined as “Phase1/2.”) “Phase 3” tests whether the new treatment is better than existing treatments.

This clinical pipeline includes completely new drugs, as well as variations of existing drugs, and new uses of existing drugs. Many of these potential treatments came out of research sponsored by the Children’s Tumor Foundation.

A few notes:

“Targets” are the part of the disease process that the drug tries to stop.

“Agents” are the drug names.

“Phases” are the current stage of research. The higher the number of the Phase, the closer the treatment is to being approved for use in NF patients.

To find out more about any of these clinical trials in the U.S., go to www.clinicaltrials.gov and search for the name of the drug, and NF. You can also find more information at www.nfregistry.org by clicking “Clinical Trials” on the menu bar. For clinical trials in Europe, search www.clinicaltrialsregister.eu.

Please click here to download an easier to read PDF of the NF clinical drug pipeline chart.

Close Menu